# Douglas J. Duchon

> Douglas J. Duchon is a startup investor at Celleration. See 0 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Celleration](https://shizune.co/investors/profile/celleration)
- Last updated: Aug 2026

Douglas J. Duchon is a startup investor at Celleration. Mr. Duchon joined Celleration in January 2011 with over 25 years of experience in the development of new products in the computer, industrial, consumer goods and medical industries. His most recent experience includes working at Hemosphere Inc. as Vice President of R&D after serving as Director of Stent Development & Technology at ev3and managing a Drug Eluting Stent Program for Boston Scientific as Sr. Program Manager. He has held senior management positions at several emerging medical companies including Advanced Bio-Surfaces, Impres Medical, and Acist Medical. Prior to becoming involved in medical product development, Mr. Duchon managed a design consultancy engineering group at Worrell Design and held various Engineering positions at Kallestad Diagnostics, Logitech, Alps Electric and Apple Computer. Mr. Duchon holds over 39 domestic and numerous international patents. He holds a Bachelor’s Degree in Mechanical Engineering from the University of Wisconsin-Madison.

## About Celleration

VC Fund · Eden Prairie, United States

Celleration, Inc., a privately held medical device company, was founded in 1999 to develop and commercialize its therapeutic ultrasound platform.Celleration’s core product, the MIST Ultrasound Healing Therapy® System delivers low frequency ultrasound through a saline mist. Unlike conventional wound treatments that are limited to treating thesurface, MIST Therapy delivers ultrasound energy into and below the wound bed to stimulate cells to positively impact all critical aspects of the wound healing process. Celleration received 510K clearance from the FDA in 2005 with the full claim of “promote wound healing”. Shortly thereafter, the company introduced the MIST Therapy System to the US market and has since built an impressive body of clinical evidence demonstrating significant clinical and economic benefits in hundreds of facilities across the United States. Currently, over over 1 million MIST® Therapy treatments have been performed in the United States and U.K. benefiting more than 65,000 patients.

5 contacts available at Celleration.

| Name | Title | Profile |
| --- | --- | --- |
| Annette Plishka | Area Director of Sales | https://shizune.co/investors/profile/annette-plishka |
| Diane M. Sahr | Vice President of Clinical Research | https://shizune.co/investors/profile/diane-m-sahr |
| Douglas J. Duchon | Vice President of Research & Development | https://shizune.co/investors/profile/douglas-j-duchon |
| Fred Taft | Area Director of Sales | https://shizune.co/investors/profile/fred-taft |
| Mark Rogozinski | Vice President of Reimbursement | https://shizune.co/investors/profile/mark-rogozinski |

## FAQ

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co